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Amyotrophic lateral sclerosis has been defined as a “heterogeneous group of neurodegenerative syndromes characterized by
progressive muscle paralysis caused by the degeneration of motor neurons allocated in primary motor cortex, brainstem, and
spinal cord.” A comprehensive diagnostic workup for ALS usually includes several electrodiagnostic, clinical laboratory and genetic
tests. Neuroimaging exams, such as computed tomography, magnetic resonance imaging and spinal cord myelogram, may also
be required. Nuclear medicine, with PET and SPECT, may also play a role in the evaluation of patients with ALS, and provide
additional information to the clinicians. This paper aims to offer to the reader a comprehensive review of the different radiotracers
for the assessment of the metabolism of glucose (FDG), the measurement of cerebral blood flow (CBF), or the evaluation of
neurotransmitters, astrocytes, and microglia by means of newer and not yet clinically diffuse radiopharmaceuticals.
1. Nuclear Medicine as Functional
and/or Molecular Imaging in the Study of
Nervous System
The living being is composed of biomolecules in dynamic
equilibrium between them in the definition of the so-called
homeostasis, which represents the physiology [1].The disease
can be considered the alteration of this system, being the
representation of an imbalance which is expressed initially as
functional impairment, sometimes reversible [2]. However,
beside the possibility of a return to normal condition, there
is the risk of further evolution towards an alteration that may
become apparent at the morphostructural level [3].
There is therefore a gradation in the progress of the
disease that can be identified according to a timeline that
shows themorphostructural modification as a late event, pre-
ceded by functional alteration [4]. Consequently, functional
imaging, that is, the representation of pathophysiological
alterations, may be more precocious in the early detection of
disease with respect to a diagnostic imaging based on mor-
phostructural premises [5]. Furthermore functional imaging
has a greater capacity in assessing the prognosis and the
relationship with the therapy in the individual patient, being
pathophysiological changes a better predictor of the evolution
of the disease and/or the effectiveness of therapeutic action
[6].
In diagnostic imaging even more interesting is the possi-
bility of studying themolecularmechanisms that underlie the
disease, allowing the representation of the initial pathological
alteration [7]. Without dwelling on technical insights, there
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are two basic systems of study: Single Photon Emission
Tomography (SPECT), which creates images using single
gamma radiations emitted by gamma-emitting radionuclides,
and Positron Emission Tomography (PET), which displays
images resulting fromdouble gammaphotons in coincidence,
which derive from annihilation of positrons [5]. Both devices
may be integrated within the so-called hybrid machines,
which have made possible a technological revolution that has
given and continues to bear fruits even in the clinical setting
[8]. Recently another promising hybrid device, PET/MRI,
was developed. PET/MRI represents an exciting novel imag-
ing option for oncological as well as neurological applications
[9].
In nuclearmedicine, it is possible to obtain a large number
of radioactive probes and then “trace” multiple functions and
molecular mechanisms in the body [7]. Through them, it is
possible to acquire sensitive and precise information, which
creates the basis for investigating the earliest levels of disease,
resulting in favourable therapeutic implications [5]. Though
the primary role in clinical diagnosis, the functional informa-
tion has however to be integrated by the morphostructural
one [10]. In this way, it is at first possible to increase the
diagnostic accuracy, better understanding and delineating
the limits of normal and pathological anatomical structures,
with a significant improvement either in sensitivity and
specificity [11]. Furthermore, because of their better spatial
resolution and/or of the different presuppositions underlying
the image, morphostructural techniques, such as CT, MRI,
andUS,may also detect abnormalities that are not visiblewith
a functional study [11].
The clinical analysis of neurological diseases with nuclear
medicine is at the present connected with three main cate-
gories of radiotracers studying (1) perfusion, (2) metabolism,
and (3) receptors [5].
Among all used radiotracers, the most important is still
the first among those proposed, namely, the F-18 fluoro-
deoxyglucose (FDG), which traces the metabolism of glu-
cose. Currently, being mainly used for oncologic applications
[12, 13], PET-FDG has a clinical interest also in nonneoplastic
pathologies, in particular in inflammatory diseases [14]. Fur-
thermore, FDG plays an important role also in the evaluation
of neurological diseases, first of all in dementia [15].
Among the most interesting applications of this method
in the brain, there is certainly that, related to Amyotrophic
Lateral Sclerosis (ALS), which is the subject of this paper.
Together with FDG, further information in ALS may be
acquired using radiotracers measuring cerebral blood flow
(CBF) or newer and not yet clinically diffuse radiopharma-
ceuticals, as those allowing the evaluation of neurotransmit-
ters, astrocytes, and microglia [16].
2. Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), also known as Charcot,
Lou Gehrig, or motor neuron’s disease, has been defined
as a “heterogeneous group of neurodegenerative syndromes
characterized by progressive muscle paralysis caused by the
degeneration of motor neurons allocated in primary motor
cortex, brainstem, and spinal cord” [17]. The disease was
identified in 1874 by JM Charcot as “a degenerative process
involving neurons in the anterior horns of the spinal cord and
inmotor nuclei of brainstem” [18]. ALS affects not onlymotor
neurons but also their nonneural neighbours, including
astrocytes and microglia, whose involvement amplifies the
initial damage and drives disease progression and spread
[19]. The main clinical variants of ALS include Primary
Muscular Atrophy (PMA), Primary Lateral Sclerosis (PLS),
and Progressive Bulbar Palsy (PBP) [19].
Being currently still unknown aetiology, many etiopat-
hogenetic hypotheses have been made for ALS. Mutations
in several genes have been demonstrated to be linked
toALS, Cu/Zn superoxide dismutase (SOD1), TARDNA-bin-
ding protein (TARDBP), the gene encoding the TAR
DNA-binding protein 43—TDP-43, the fused in sarcoma/
translocated in liposarcoma (FUS/TLS) protein, and chromo-
some 9 open reading frame 72 gene (C9ORF72) being the
most important [20]. Other mutated genes involved in ALS
are PFN1, OPTN, VCP, UBQLN2, ANG, FIG4, DCTN1, and
CHMP2B [20]. FurthermoreALS has been related to (1) effect
of exotoxins, which would lead to an excessive stimulation
of glutaminergic postsynaptic NMDA and AMPA receptors;
(2) oxidative stress, with accumulation of reactive oxygen;
(3) mitochondrial dysfunction, with morphological and bio-
chemical abnormalities. Among the factors involved are also
included the alteration of the axonal transport, the deposit of
aggregates of proteic neurofilaments, the dysfunction of glial
cells, and the deficit of neurotropic factors [19].
With regard to the possibility of a role of genetic factors,
it should be remembered that the disease is expressed in
90% of cases as sporadic form, being identified as a familiar
disease, with autosomal dominant inheritance, in less than
10% of patients. Being a little more frequent in males (M/F
= 1.3), ALS has an average age of onset at 55–65 years. The
incidence is 1.5–2.7 and the prevalence is 2.7–7.4 per 100,000
inhabitants/year. Progression and severity can vary greatly
from one patient to another. The mortality rate is 1.54–2.55
per 100,000 patients, with a median survival of 3–5 years.The
main cause of death is the failure of the respiratory muscles
[21].
3. Diagnostic Workup of ALS
ALS is a very difficult disease to diagnose and at the present
there is no test or procedure to confirm without any doubt
the final diagnosis [22]. More frequently, clinical suspicion
emerges through a careful clinical examination, repeated over
time by an expert neurologist, and a series of diagnostic
tests to rule out other possible disorders justifying clinical
symptoms. According to ALS Association (fighting Lou
Gehrig’s disease) a comprehensive diagnostic workup has to
include most, if not all, of the following procedures [21]:
(i) electrodiagnostic tests including conventional elec-
tromyography (EMG), nerve conduction studies,
transcranialmagnetic stimulation, centralmotor con-
duction studies, and quantitative electromyography
(ii) neuroimaging including computed tomography (CT)
scanning or magnetic resonance imaging (MRI) of
the brain and spinal cordmyelogramof cervical spine,
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(iii) clinical laboratory tests which will include muscle
enzymes (serum creatine kinase (unusual above ten
times upper limit of normal), ALT, AST, and LDH),
serum creatinine (related to loss of skeletal muscle
mass), hypochloremia, increased bicarbonate (related
to advanced respiratory compromise), and elevated
CSF protein (uncommonly more than 100mg/dL)
(iv) muscle and/or nerve biopsy,
(v) genetic testing.
The clinical role of diagnostic imaging, mainly inter-
preted by MRI, is mainly individuated in excluding alterna-
tive diseases, being nontypical and/or difficult to be detected
diagnostic signs univocally defining ALS. Being this disease
strictly connected with the motor neuron, the pathological
damage should be evidenced exclusively at the level of the
motor cortex and/or at the level of the subcortical structures
involved in the motor system [21].
The currently most used diagnostic criteria for ALS are
those of El Escorial World Federation of Neurology [23],
which divide ALS into 5 diagnostic categories: clinically
definite ALS, clinically probable ALS, clinically probable-
laboratory supported ALS, and clinically possible ALS
(Table 1).
4. Glucose Metabolism and Cerebral Blood
Flow in ALS Patients
Either glucose metabolism or cerebral blood flow is similarly
reduced in patients with ALS [24–29]. Surprisingly, since first
studies with FDGPET performed in early 80’s [30] in patients
with upper motor neuron signs compared to age-matched
control subjects, a decreased activity was observed not only
in themotor primary and accessory medial motor cortex, but
also at level of parietal and occipital lobes, being spared visual
areas.
A frontal lobe dysfunctionwas also demonstrated in non-
demented ALS patients by Abrahams et al. [31], measuring
cerebral blood flow (rCBF) with PET. The study was based
on an activation paradigm of executive frontal lobe function
(verbal fluency), which contrasted with rCBF during word
generation and word repetition. A PET scan was performed
in groups of age matched individuals constituted by patients
with ALS, respectively, affected (ALSi = impaired) or not
(ALSu = unimpaired) with a cognitive impairment, both
compared with healthy controls. The ALSi subjects displayed
significantly impaired activation in cortical and subcortical
regions including the dorsolateral prefrontal cortex, lateral
premotor cortex, medial prefrontal and premotor cortices,
and insular cortex bilaterally and the anterior thalamic
nuclear complex. Although the three groups showedmatched
word generation performance on the scanning paradigm,
the ALSu group displayed a relatively unimpaired pattern of
activation.These results are in agreement with an extramotor
neuronal involvement in some non-demented ALS patients
that develops probably along a thalamo-frontal association
pathway.
Dalakas et al. [24], using FDG PET, observed that in
patients with upper motor neuron signs, the mean cortical
Regional Cerebral Metabolic Rate of Glucose Consumption
(rCMRGlc) was significantly lower than in normal subjects.
Moreover, subsequent reduction in the rCMRGlc, in agree-
ment with the clinical worsening, was observed in 3 out of the
4 patients who underwent repeated PET scan. Conversely, a
normal or near-normal rCMRGlc was seen throughout the
brain in ALS patients with disease confined to lower motor
neurons and in 3 subjects with lower motor neuron dis-
ease, depending from old paralytic poliomyelitis. As already
observed in cerebellar diaschisis [32], these data demonstrate
that a hypometabolism may be seen in a structurally normal
cortex, in case of functionally altered neurons neurologically
connected with dead and/or dedifferentiated cells. Hatazawa
et al. [25] reported a more detailed regional analysis con-
cerning almost the same population studied by Dalakas,
also including the evaluation of the motor-sensory cortex at
higher levels than used earlier. A brain size correction was
added to avoid differences in measured activity depending
on brain size, but not from hypometabolism. In this more
detailed analysis, a generalized reduction of FDG’s uptakewas
shown in patients with both upper and lower motor neuron
disease that was greatest in the motor-sensory cortex and
putamen. The motor-sensory deficit was strongly correlated
with length of disease, and a marked sequential reduction
was seen in the four patients who repeated a PET study. In
this paper, a right-left asymmetry in the population described
above and a normal or near normal FDG uptake in the
four ALS patients without upper motor neuron involvement
were also reported. In 2007, the correlation of the extent of
cortical lesions with the intensity of motor dysfunction in
ALS patients, measured by the ALS functional rating scale
score (ALSFRS), has been also studied by Habert et al. [33],
who evaluated cerebral perfusion using SPECT with 99mTc-
ECD and a statistical parametric mapping (SPM) method.
A positive correlation between the degree of involvement
of the motor functions and the perfusion decrease of the
cerebral cortex was demonstrated. Analyzing the ALSFRS
subscores, the cortical involvement was important for lower
limbs score, moderate for bulbar score, and below the level
of statistical significance for the respiratory and upper limb
scores. An asymmetric hypoperfusion, because of a major
involvement of the right hemisphere, was seen mainly in the
lateral premotor cortex, the insula, and the cingulate cortex.
5. Different Patterns of Glucose Metabolism in
ALS Patients
Using PET-FDG, different patterns of hypometabolism have
been observed when the motor neuron disease (MND)
coexists with Frontotemporal Dementia (FTD). Comparing
patients with FTD and MND with subjects affected with
FTD alone Jeong et al. [34] demonstrated that the patients
with FTD/MND showed glucose hypometabolism only in
the frontal area, whereas most patients with FTD had
hypometabolism in the frontal and temporal areas. Further-
more, in case of FTD/MND, a more symmetric pattern of
hypometabolism with respect to patients with FTD alone
was showed. To better understand the FDG distribution in
patients with FTD, Jeong performed also an SPM analysis
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Table 1: ALS diagnostic categories according to the El Escorial World Federation of Neurology diagnostic criteria.
Clinically definite ALS Defined on clinical evidence alone by the presence of UMN, as well as LMN signs,in three regions
Clinically probable ALS Defined on clinical evidence alone by UMN and LMN signs in at least two regionswith some UMN signs necessarily rostral to (above) the LMN signs.
Clinically probable-laboratory-supported ALS
Defined when clinical signs of UMN and LMN dysfunction are in only one region,
or when UMN signs alone are present in one region, and LMN signs defined by
EMG criteria are present in at least two limbs, with proper application of
neuroimaging and clinical laboratory protocols to exclude other causes.
Clinically possible ALS
Defined when clinical signs of UMN and LMN dysfunction are found together in
only one region or UMN signs are found alone in two or more regions; or LMN
signs are found rostral to UMN signs and the diagnosis of clinically
probable-laboratory-supported ALS cannot be proven by evidence on clinical
grounds in conjunction with electrodiagnostic, neurophysiologic, neuroimaging, or
clinical laboratory studies. Other diagnoses must have been excluded to accept a
diagnosis of clinically possible ALS
in comparison with normal controls [35]. A significant
hypometabolism was identified in extensive prefrontal areas,
cingulate gyri, anterior temporal regions, and the left inferior
parietal lobule and less relevant in the bilateral insula and
uncus, left putamen and globus pallidus, andmedial thalamic
structures. Frontal hypometabolism was more frequently
prominent in the left hemisphere than in the right.
Cistaro et al. [36] studied with FDG PET 32 patients
with ALS, of either bulbar (𝑛 = 13) or spinal (𝑛 =
19) onset, compared by SPM with 22 subjects taken as
controls. Patients with spinal onset had significantly higher
scores in a neuropsychological test assessing verbal fluency
compared with patients with bulbar onset. In this study an
unprecedented evidence of relatively increased metabolism
in the amygdalae, midbrain, and pons was observed in ALS
patients as compared with control subjects, possibly due to
local activation of astrocytes andmicroglia.Highly significant
relative decreases in metabolism were found in large frontal
and parietal regions in the bulbar onset patients as compared
with the spinal onset subjects and the controls, suggesting a
differential metabolic and neuropsychological state between
the two conditions.
Data of Cistaro et al. [36] are in agreement with an
increased metabolism along the course of the cerebral spinal
fluid (CSF), at level of pons and midbrain. The hyperme-
tabolism could depend on a colonization of the pyramidal
tract by active astrocytes and/or microglia. Interestingly a
reduced fractional anisotropy has been observed in the pons
and along the CSF in patients who underwent either PET or
fMRI [37]. With respect to the hypometabolism observed in
patients with a bulbar onset, our results support the presence
of an extramotory involvement in ALS which may interest
dorsolateral and prefrontal cortex. Conversely, a normal or
near normal frontoparietal FDG uptake has been observed
in ALS patients with a spinal onset.
In 2014, Cistaro et al. performed another study, valuat-
ing the FDG PET profile of 15 patients with familial ALS
carrying the GGGGCC hexanucleotide repeat expansion in
the C9ORF72 gene and comparing them with a group of 12
patients with ALS and comorbid frontotemporal dementia
(FTD) without the C9ORF72 expansion (ALS-FTD), a group
of 30 cognitively normal patients and 40 normal controls.
The authors demonstrated that, among the 4 groups, patients
carrying the C9ORF72 mutation show a more extensive
involvement of the central nervous system, with significant
hypometabolism in the anterior and posterior cingulate
cortex, insula, caudate, and thalamus, the left frontal and
superior temporal cortex, and hypermetabolism in the mid-
brain, bilateral occipital cortex, globus pallidus,, and left
inferior temporal cortex [38].
6. Microglia Involvement in ALS Patients
The explanation of subcortical hypermetabolic areas as a
possible consequence of a colonization by active astrocytes
and/or microglia is in agreement with the new view of FDG’s
cerebral uptake, which changed in the last decades [39]. It has
been demonstrated that glucose is not consumed exclusively
by neurons and that glucose consumption does not directly
reflect only neural activity [40]. In this respect, the impor-
tance of astrocytes in glutamate-driven glucose metabolism
and regulation has been highlighted [40], supporting the
indication that also cells other than neurons are involved in
FDG’s uptake.
The evidence of widespread cerebral microglial activation
in amyotrophic lateral sclerosis may be further understood
reading the paper by Turner et al. [41], who reported an
experience with [11C](R)-PK11195, a ligand for the periph-
eral benzodiazepine binding site, expressed by activated
microglia. The PET study has been performed in ten ALS
patients and 14 healthy controls. Significantly increased
binding was found in motor cortex, pons, dorsolateral
prefrontal cortex, and thalamus in the ALS patients, with
significant correlation between binding in the motor cortex
and the burden of upper motor neuron signs clinically
evident.This paper supports the interest for the development
of therapeutic strategies in ALS aimed at inflammatory
pathways. Favourable results have already been obtained in
experimental models where an increased survival has been
observed in animals when treated with anti-inflammatory
drugs. To demonstrate the relevance of astrocytosis in ALS,
Johansson et al. [42] utilized [11C](L)-deprenyl-D2, which
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binds to the enzymeMAO-B, primarily located in astrocytes.
An increased uptake of deuterium-substituted [11C](L)-
deprenyl PET was demonstrated in pons and white matter
of seven patients with ALS, compared with seven healthy
control subjects.
7. Evaluation of ALS Patients with PET
Receptor Studies
An original study has been published by Lloyd et al. [43],
who evaluated extramotor involvement in ALS, using as PET
radiotracer the [(11)C]flumazenil (FMZ), a benzodiazepine
GABA(A) marker. The study was performed in seventeen
nondemented patients with clinically definite or probable
ALS compared with seventeen normal controls. The analysis
was based on SPM maps, derived to localize changes in
regional flumazenil volumes of distribution (FMZVD),which
correlate closely with receptor density. Relative FMZVD was
significantly decreased in the ALS group in the prefrontal
cortex, parietal cortex, visual association cortex, and left
motor/premotor cortex. A relative reduction in FMZVD was
also present, though less evident, in the left ventrolateral
and dorsolateral prefrontal cortex, Broca’s area, and the right
temporal and right visual association cortex. These data are
in agreement with a cerebral dysfunction in ALS which
involves not only the motor cortex, but also premotor and
extramotor areas, particularly in the prefrontal regions. A
more recent study using [11C]flumazenil (FMZ) PET has
been performed by Turner et al. [44], who focalized their
interest in patients with ALS, also including subjects who
presented the “D90A” SOD1 mutation. The mutations of the
superoxide dismutase-1 (SOD1) gene are associated with five
to ten percent cases of ALS. Between them, the “D90A”
mutation individuate a unique phenotype, characterized by
a markedly slower disease progression, with a mean survival
of 14 years, probably dependent on the relative sparing of
inhibitory cortical neuronal circuits. The study has been
based on the comparison of results obtained in twenty-four
sporadicALS (sALS), 10 homozygousD90Apatients, and two
subjects homozygous for the D90A mutation, but without
symptoms or signs (“presymptomatic”, psD90A), with those
achieved in 24 age-matched normal controls. While in sALS
a decreased uptake has been observed within premotor
regions, motor cortex, and posterior motor association areas;
in the homD90Agroup the reductionwas concentrated in the
left frontotemporal junction and anterior cingulate gyrus. In
the two psD90A subjects, a small focus of reduced uptake was
seen at the left frontotemporal junction, therefore showing a
pattern similar to the one observed in the clinically affected
patients. No statistically significant association between the
reduction in cortical FMZ binding and revised Amyotrophic
Lateral Sclerosis Functional Rating Scale (ALSFRS) was
demonstrated in sALS patients, whereas the upper motor
neuron (UMN) score correlatedwithwidespread andmarked
cortical decreases over the dominant hemisphere. Conversely,
in theD90Agroup, the decreased in FMZuptakewas strongly
statistically associated with ALSFRS-R, rather than the UMN
score, being also related to the disease’s duration.
To evaluate the possible interest of dopaminergic radio-
tracers in ALS, Takahashi et al. [45] utilized F-18 fluorodopa
in 16 patients with sporadic ALS and without extrapyramidal
disease, compared with age-matched controls. A significant
progressive fall in fluorodopa uptake was observed in 3
patients with ALS of long duration.
The possible interest of radiotracers of serotonin was
inquired by Turner et al. [41], who performed PET with
[11C]-WAY100635 PET, a sensitive marker of in vivo 5-HT1A
receptor binding, inALS patients comparedwith controls. An
SPM analysis evidenced a striking and widespread decrease
in cerebral 5-HT1A binding in ALS patients compared with
controls in bothmotor and extramotor regions, with themost
marked changes in frontotemporal regions. Their hypothesis
was that these findings reflect widespread damage to cortical
pyramidal neurones that express 5-HT1A receptors, although
a purely functional change in receptor binding cannot be
excluded.
8. Conclusion
In the older definition ALS is considered as a disease
exclusively characterized by preferential loss of motor neu-
rons in the motor cortex, brainstem, and spinal cord, that
is, by a pathological involvement exclusively of the motor
system. Although they do not have yet been included in
the clinical scenario, PET and SPECT may give interesting
information in these patients, having capability to trace
many important pathophysiological and biochemical targets
involved in the disease. The greatest advantage achievable
by molecular imaging is in individuating early functional
alterations, preceding the morphostructural evidence, better
explaining clinical symptoms, as those connected with a
frontal dementia, and helping to define a prognostic strati-
fication. At the present, clinical information may be mainly
acquired using PET-FDG. Important data, to be utilized as
premise to a therapeutic strategy based on inflammation
as a target, could be achieved with radiotracers allowing
to detect astrocytosis. Finally, having been demonstrated a
possible role of fMRI in detecting alterations in fractional
anisotropy, at level of subcortical structures, very intriguing
perspectives could be associated with the diffusion of PET-
MRI hybrid machines, allowing obtaining simultaneously,
together with the morphostructural information, functional
data acquirable either with PET or fMRI.
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